Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes

Monami, Matteo; Lamanna, Caterina; Lambertucci, L.; Longo, Rebecca; Cocca, Carmen; Addante, Filomena; Lotti, Elena; Masotti, Giulio; Marchionni, Niccolò; Mannucci, Edoardo

doi:10.1007/bf03344161

Cited by 15 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the impact of reduced PPG may to some extent be indirectly included in the present analysis, as HbA1c was used as the measure of glycaemic control. Some studies have suggested that PPG makes a significant contribution to HbA1c in patients who are relatively well controlled, although other studies have been more cautious and have suggested that fasting plasma glucose is a better indicator of HbA1c, particularly in patients with a very high HbA1c concentration …”

Section: Discussionmentioning

confidence: 99%

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

Russell‐Jones

Heller

Buchs

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo assess the impact of faster aspart vs insulin aspart on long‐term clinical outcomes and costs for patients with type 1 diabetes mellitus (T1DM) in the UK setting.MethodsThe QuintilesIMS CORE Diabetes Model was used to project clinical outcomes and costs over patient lifetimes in a cohort with data on baseline characteristics from the “onset 1” trial. Treatment effects were taken from the 26‐week main phase of the onset 1 trial, with costs and utilities based on literature review. Future costs and clinical benefits were discounted at 3.5% annually.ResultsProjections indicated that faster aspart was associated with improved discounted quality‐adjusted life expectancy (by 0.13 quality‐adjusted life‐years) vs insulin aspart. Improved clinical outcomes resulted from fewer diabetes‐related complications and a delayed time to their onset with faster aspart. Faster aspart was found to be associated with reduced costs vs insulin aspart (cost savings of £1715), resulting from diabetes‐related complications avoided and reduced treatment costs.ConclusionsFaster aspart was associated with improved clinical outcomes and cost savings vs insulin aspart for patients with T1DM in the UK setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

Russell‐Jones

Heller

Buchs

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Concurrent measurements of fasting plasma glucose and HbA 1c levels during stable therapy are strongly correlated, [4,5]. However, when treatment is intensified, fasting plasma glucose values improve immediately, whereas HbA 1c values lag behind, not reaching a stable new value for 4 months or more.…”

Section: Introductionmentioning

confidence: 99%

Fasting plasma glucose 6–12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis

Karl¹,

Zhou

Vlajnic

et al. 2012

Diabetic Medicine

View full text Add to dashboard Cite

AimsTo evaluate whether fasting plasma glucose values measured early during insulin therapy can identify patients with Type 2 diabetes who may not achieve adequate glycaemic control after 6 months and will require additional treatment.MethodsPatient-level data from seven prospective, randomized, controlled studies using treat-to-target methods were pooled to evaluate the efficacy of insulin glargine. Fasting plasma glucose was measured at baseline, week 6 or 8 (6/8) and week 12. HbA1c was measured at week 24 to assess glycaemic control.ResultsOne thousand and thirty-six patients (56% male, 81% white) were included in the analysis (mean age 56.3 years; duration of diabetes 8.4 years). Baseline mean fasting plasma glucose was 11.2 mmol/l and mean HbA1c was 73 mmol/mol (8.8%). After 24 weeks of treatment, mean HbA1c decreased to 53 mmol/mol (7.0%); 56% of patients reached a target HbA1c≤ 53 mmol/mol (7.0%). Significant correlations with week 24 HbA1c were obtained for fasting plasma glucose measured at week 6/8 and week 12 (r = 0.32; P < 0.0001 for both). Patients with fasting plasma glucose > 10 mmol/l at week 6/8 or week 12 were significantly less likely to achieve the HbA1c target at the end of treatment than patients with fasting plasma glucose < 8.9 mmol/l (P < 0.0001 for both). If fasting plasma glucose was > 10 mmol/l at week 6/8 or week 12, patients had only a 27% chance of reaching the HbA1c goal.ConclusionsFasting plasma glucose remaining > 10 mmol/l after 6–12 weeks of glargine therapy indicates that reaching target HbA1c≤ 53 mmol/mol (7.0%) is unlikely and calls for individualized attention to consider further therapeutic options.

show abstract

“…In hyperglycaemia (post-prandially or in non-controlled diabetes) and to a lesser extent in normoglycaemia, both circulatory proteins and proteins of the endothelium are exposed to (excess) glucose, leading to the slow formation of AGE ( 8 – 11 ) . During that process, glycation adducts are created on the protein molecule, as a function of glucose levels.…”

Section: Importance Of Glycation For Healthmentioning

confidence: 99%

Oxidative stress, protein glycation and nutrition – interactions relevant to health and disease throughout the lifecycle

2014

View full text Add to dashboard Cite

Protein glycation has been studied for over a century now and plays an important role in disease pathogenesis throughout the lifecycle. Strongly related to diabetic complications, glycation of Hb has become the gold standard method for diabetes diagnosis and monitoring. It is however attracting attention in normoglycaemia as well lately. Longitudinal studies increasingly suggest a positive relationship between glycation and the risk of chronic diseases in normoglycaemic individuals, but the mechanisms behind this association remain unclear. The interaction between glycation and oxidative stress may be particularly relevant in the normoglycaemic context, as suggested by recent epidemiological and in vitro evidence. In that context nutritional and lifestyle factors with an influence on redox status, such as smoking, fruit and vegetable and antioxidants consumption, may have the capacity to promote or inhibit glycation. However, experimental data from controlled trials are lacking the quality and rigour needed to reach firm conclusions. In the present review, we discuss the importance of glycation for health through the lifecycle and focus on the importance of oxidative stress as a driver for glycation. The importance of nutrition to modulate glycation is discussed, based on the evidence available and recommendations towards higher quality future research are made.

show abstract

Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes

Cited by 15 publications

References 16 publications

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

Fasting plasma glucose 6–12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis

Oxidative stress, protein glycation and nutrition – interactions relevant to health and disease throughout the lifecycle

Contact Info

Product

Resources

About